We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

3 hedge funds and large institutions have $118K invested in Scinai Immunotherapeutics in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

3% less capital invested

Capital invested by funds: $122K → $118K (-$4K)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$5.17K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
1
Vantage Investment Advisors
Pennsylvania
$60K – – –
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$53K – – –
UBS Group
3
UBS Group
Switzerland
$5K +$5.17K +14 New
TRCT
4
Tower Research Capital (TRC)
New York
– -$3K -8 Closed

SCNI Hedge Fund Activity: Q2 2016 in Review

3 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2016, worth a combined $118K — down 3.3% from $122K a quarter earlier.

Fund positioning in SCNI was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $5.17K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3K sold.

  • 3 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $118K of Scinai Immunotherapeutics stock for Q2 2016, down 3.3% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q2 2016 and 1 closed out, a net change of 0 holders.
  • The largest Scinai Immunotherapeutics buyer in Q2 2016 was UBS Group, an estimated $5.17K added.
  • The largest Scinai Immunotherapeutics seller in Q2 2016 was Tower Research Capital (TRC), an estimated $3K sold.

Based on aggregated 13F filings for Q2 2016.